Quick Answer
Autolus Therapeutics plc reported Total Revenue of $75.39 million for fiscal year 2025.
Autolus Therapeutics plc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $75.39M +644.9% |
$10.12M +496.0% |
$1.70M | — | — | — |
| Revenue (ASC 606) | $75.39M +644.9% |
$10.12M | — | — | — | — |
| Net Income | -$287.53M -30.3% |
-$220.66M -5.9% |
-$208.38M -40.0% |
-$148.84M -4.7% |
-$142.10M -0.0% |
-$142.09M -14.7% |
| Diluted EPS | -$1.08 -25.6% |
-$0.86 +28.3% |
-$1.20 +23.6% |
-$1.57 +20.3% |
-$1.97 +28.6% |
-$2.76 +4.2% |
| Total Assets | $589.07M -24.7% |
$782.73M +70.2% |
$459.97M +26.4% |
$363.99M -10.2% |
$405.56M +37.8% |
$294.24M -3.1% |
| Cash and Equivalents | $104.13M -54.2% |
$227.38M -33.7% |
$343.03M +27.7% |
$268.56M -13.5% |
$310.34M | — |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $178.13M -58.3% |
$427.32M +60.1% |
$266.92M -1.6% |
$271.14M -13.5% |
$313.32M +49.2% |
$210.03M -17.6% |
| R&D Expense | $117.69M -15.0% |
$138.44M +6.1% |
$130.48M +11.2% |
$117.35M +5.9% |
$110.84M -17.8% |
$134.89M +28.0% |
| Operating Income | -$270.54M -12.1% |
-$241.43M -34.3% |
-$179.70M -25.3% |
-$143.41M -1.7% |
-$141.05M +16.1% |
-$168.15M -15.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $21.19M | — | +1.3% |
| Revenue (ASC 606) | September 30, 2025 | $21.19M | — | +1.3% |
| Net Income | September 30, 2025 | -$79.12M | +3.6% | -65.1% |
| Diluted EPS | September 30, 2025 | -$0.30 | +3.2% | -66.7% |
| Total Assets | September 30, 2025 | $661.95M | -20.0% | -8.2% |
| Cash and Equivalents | September 30, 2025 | $86.12M | -86.9% | -30.4% |
| Stockholders Equity | September 30, 2025 | $265.45M | -44.3% | -23.4% |
| R&D Expense | September 30, 2025 | $27.89M | -30.8% | +1.7% |
| Operating Income | September 30, 2025 | -$71.62M | -5.5% | -17.0% |
- Autolus Therapeutics plc reported Total Revenue of $75.39 million for fiscal year 2025.
- Autolus Therapeutics plc showed an increase of +644.9% in Total Revenue compared to the prior fiscal year.
- Autolus Therapeutics plc reported Revenue (ASC 606) of $75.39 million for fiscal year 2025.
- Autolus Therapeutics plc showed an increase of +644.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Autolus Therapeutics plc reported Net Income of -$287.53 million for fiscal year 2025.
- Autolus Therapeutics plc showed a decrease of -30.3% in Net Income compared to the prior fiscal year.
- Autolus Therapeutics plc reported Diluted EPS of $1.08 per share (loss) for fiscal year 2025.
- Autolus Therapeutics plc showed a decrease of -25.6% in Diluted EPS compared to the prior fiscal year.
- Autolus Therapeutics plc reported Total Assets of $589.07 million for fiscal year 2025.
- Autolus Therapeutics plc showed a decrease of -24.7% in Total Assets compared to the prior fiscal year.
- Autolus Therapeutics plc reported Cash and Equivalents of $104.13 million for fiscal year 2025.
- Autolus Therapeutics plc showed a decrease of -54.2% in Cash and Equivalents compared to the prior fiscal year.
- Autolus Therapeutics plc reported Long-Term Debt of $0.00 for fiscal year 2019.
- Autolus Therapeutics plc showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Autolus Therapeutics plc reported Stockholders Equity of $178.13 million for fiscal year 2025.
- Autolus Therapeutics plc showed a decrease of -58.3% in Stockholders Equity compared to the prior fiscal year.
- Autolus Therapeutics plc reported R&D Expense of $117.69 million for fiscal year 2025.
- Autolus Therapeutics plc showed a decrease of -15.0% in R&D Expense compared to the prior fiscal year.
- Autolus Therapeutics plc reported Operating Income of -$270.54 million for fiscal year 2025.
- Autolus Therapeutics plc showed a decrease of -12.1% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: